Men diagnosed at this hospital trust can access the following services:

• Diagnostic Facilities:
• Multiparametric MRI
• Transperineal biopsy under local anaesthetic
• Transperineal biopsy under general anaesthetic
• PSMA (prostate-specific membrane antigen) PET scan
• Isotope bone scan

• Treatment Facilities:
• Chemotherapy
• Joint specialist MDT clinic

• Support Service Facilities:
• Clinical Nurse Specialist (CNS) in all clinics
• Prostate cancer-specific CNSs
• Advanced PCa CNS
• Urology CNS
• Sexual function services
• Specialist continence services
• Psychological counselling
• Onco-geriatric service

For Wales, this data completeness relates to patients diagnosed between April 2022 and March 2023.
For England, this data completeness relates to patients diagnosed in 2021. This is the data completeness of the National Cancer Registration Dataset (NCRD). For data completeness of the Rapid Cancer Registration Dataset (RCRD), please refer to the NPCA quarterly reports.

	Diagnosing Trust	Specialist MDT
No. of Cancer Registry records	488	1065
Performance Status recorded	87%	42%
PSA completed	81%	59%
Gleason Score completed	82%	82%
TNM completed	75%	64%

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

	Specialist MDT	National
No. of men with disease status determined	904	39897
Percentage of men diagnosed with metastatic disease	12%	17%

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

	Specialist MDT	National
No. of men diagnosed with low-risk localised disease	90	4684
Percentage of men with low-risk localised disease receiving radical treatment	7%	8%
No. of men diagnosed with locally advanced disease	346	15410
Percentage of men diagnosed with locally advanced disease receiving radical treatment	53%	68%